Reverse transduction, also known as substrate-mediated gene delivery, is a strategy in which viral vectors are first coated onto a surface that subsequently comes into 
A prior study evaluated transduction outcomes of several mammalian cell lines in 96-well tissue culture plates immobilized with different AAV serotypes (Dong et al., 2010) . The multiplicities of infection (MOIs)-number of viral genomes added per cell-necessary to produce optimal results were reported in the range of 20,000-40,000. Another study demonstrated the feasibility of developing live-cell microarrays by depositing AAV2 onto nitrocellulose-coated slides, resulting in effective reverse transduction when HeLa cells were seeded on top of these surfaces (McConnell, Schweller, Diehl, & Suh, 2011) .
AAV-based reverse transduction has also been used in various studies relevant to tissue engineering. For example, transduction efficiency resulting from AAV2 patterned onto different substrate coatings, including extracellular matrix (ECM) components, has been evaluated (McConnell, Gomez, & Suh, 2012; McConnell, Slater, Han, West, & Suh, 2011) . Understanding the interaction between AAV vectors and ECM proteins is particularly relevant because the latter are present in all tissues and organs, as well as being frequently incorporated into scaffolds for tissue regeneration. A number of other studies have also pursued a combined biomaterial and AAV approach. In one instance, AAV2 encoding for vascular endothelial growth factor and receptor activator of nuclear factor kappa-B ligand have been incorporated into bone allografts, and after implantation in mice, bone remodeling was observed (Ito et al., 2005) . Bone morphogenetic protein-2 (BMP2)-expressing AAV2 has also been coated onto hydroxyapatite in a similar fashion and demonstrated to induce bone formation in a rat model (Nasu et al., 2009 ). More recently, a group generated poly(L-lactic acid) scaffolds incorporating AAV encoding BMP2 and evaluated the osteogenic potential in vitro and in vivo with seeded human mesenchymal stem cells (hMSCs) (Xue et al., 2017) .
Despite encouraging outcomes seen from the aforementioned examples, some studies have also reported low transduction efficiencies. In one instance, a self-complementary AAV2.5 vector harboring the LacZ reporter transduced less than 2% of hMSCs in vitro (at MOIs 20,000 and 40,000) (Dupont et al., 2012) .
The performance of a given gene delivery vehicle exhibits large variability amongst different cell types, and AAV is certainly not exempt from this challenge. Ellis et al. (2013) conducted a comprehensive in vitro screen, whereby they performed standard transduction on 34 human and animal cell lines with a panel of AAV serotypes. Widely variable gene expression outcomes were observed, with a handful of cell types refractory to AAV even at a high MOI of 100,000 (Ellis et al., 2013) . To expand the use of AAV vectors for as many applications as possible, easy methods for improving the testing of AAV transduction would be valuable, especially in cell types difficult to transduce in vitro. Although AAV2 is most well characterized and frequently used historically, expanding the delivery capabilities of other serotypes would be advantageous to harness their full potential.
In this study, we evaluated three AAV serotypes previously shown to display high (AAV2), moderate (AAV9), and low (AAV7) transduction efficiencies in HeLa cells in vitro (Ellis et al., 2013) 
| Standard AAV transduction
HeLa cells were seeded at 1.35 × 10 5 cells per well on 24-well tissue culture plates that were coated with poly(L-lysine). After 24 hr, virus suspended in Dulbecco's modified Eagle medium (DMEM; Gibco) with 10% fetal bovine serum (FBS; Gemini) and 1% Penicillin/ Streptomycin (P/S; Gibco) was added to the cells. Culture medium was replaced 24 hr following transduction.
| Reverse AAV transduction
Amicon-purified virus was diluted in 1X gradient buffer containing 0.001% Pluronic F-68 based on desired MOIs and dispensed onto tissue culture plates. The plates were then stored at 4°C overnight. Before cell seeding, the virus solution was aspirated from the wells. HeLa cells were seeded at 2.7 × 10 5 cells per well onto virus-coated 24-well tissue culture plates. Culture medium was replaced 24 hr posttransduction.
| Fluorescence imaging to visualize transduced cells
At 48 hr posttransduction, HeLa cells in the tissue culture plates were imaged on a Nikon Eclipse TE300 inverted fluorescence microscope (Nikon, Tokyo, Japan) using a 10× objective. Brightfield images were taken with an exposure time of 4 ms. An fluorescein isothiocyanate (FITC) filter and fluorescence lamp set to 25% output were used to capture GFP-positive cells, employing a 500 ms exposure time. The Bio-Formats package in MATLAB was used for image postprocessing to improve brightness and contrast.
Look-up table values were restricted between 0.005 and 0.02 and applied uniformly across all images.
| Flow cytometry to quantify gene delivery efficiency
HeLa cells from both standard and reverse transduction assays were detached from their respective tissue culture plates using trypsin followed by serum media neutralization of the protease. 
| Virus internalization assay

| Statistical analysis
All results are reported as mean ± standard error of the mean. An unpaired Student's t test was used to determine if there was any significant difference at p < 0.05 between standard and reverse transduction methods for a specific AAV serotype at a given MOI.
Statistical analyses were carried out in R using the t.test() function with inputs of all the TI values comprising the groups being compared. in HeLa cells for both formats (Figure 3) . Surprisingly, however, reverse transduction does not improve the performance of AAV2 relative to standard transduction. In fact, standard transduction seems to yield greater gene expression for this AAV serotype.
We then tested the two transduction formats for AAV7 and AAV9. In contrast to the results for AAV2, the transduction efficiency for both AAV7 (Figure 4 ) and AAV9 ( Figure 5 ) markedly increases with reverse transduction compared with the standard transduction. One interesting observation for AAV7 is the foldchange increase in efficiency due to using the reverse format increases with higher MOI (Figure 4d ). In other words, for AAV7, the fold-improvement gained by using reverse transduction is better when more viruses are used. It is possible that there may be some synergistic effects when using higher MOIs (e.g., viruses can escape endosomes more easily when there are more viruses in the vesicle transduction might be particularly beneficial when using serotypes to which a given cell type is less permissive in vitro. In the case of serotypes to which a particular cell line is already highly permissive, the reverse format may not yield improvements in efficiency.
To provide further context, we compare our results to that of Ellis et al., who also packaged a self-complementary AAV expressing GFP under a constitutive CMV promoter. They reported 80%, 20%, and 38% GFP-positive cells for AAV2, AAV7, and AAV9, respectively, at MOI 100,000 in HeLa cells by standard transduction. In our study, we observed 76%, 7%, and 12% GFP-positive cells for AAV2 (MOI 1000), AAV7 (MOI 10,000), and AAV9 (MOI 10,000), respectively, for standard transduction. In addition, we achieve 56%, 50%, and 43% GFP-positive cells for AAV2 (MOI 1000), AAV7
(MOI 10,000), and AAV9 (MOI 10,000), respectively, for reverse transduction.
| Increased cellular uptake does not fully explain improved transduction efficiency
We next sought to determine if increased cellular uptake of the viral vectors leads to increased gene delivery efficiencies under the standard or reverse transduction formats. We posited that reverse transduction may facilitate greater virus uptake compared with standard transduction (at least for AAV7 and AAV9), as the former strategy forces cells to come into contact with viruses as they settle and attach to the bottom of the plate where the viruses are immobilized.
Interestingly, results from the cellular internalization assay neither fully support nor dispel this hypothesis ( Figure 6 ). For AAV7, the 6.3-fold increase in cellular uptake of vectors noted for reverse transduction may possibly explain the 7.1-to 12.8-fold The binding receptors of AAV7 remain unidentified. AAV9's primary receptor is N-terminal galactose (Shen, Bryant, Brown, Randell, & Asokan, 2011) , and its coreceptor is laminin (Akache et al., 2006) . The galactose binding pocket of AAV9 comprises five amino acids (N470, D271, N272, Y446, W503) situated at the base of protrusions surrounding the capsid's threefold axes of symmetry (Bell, Gurda, Van Vliet, Agbandje-McKenna, & Wilson, 2012) . Moreover, AAVR is a recently identified receptor shown to be necessary for infection by multiple variants, including AAV2 and AAV9 (Pillay et al., 2016; Pillay et al., 2017) . It is plausible that AAV vectors may use different routes of cellular entry and subsequent intracellular trafficking depending on whether they are subjected to standard or reverse transduction formats, and follow-up studies are necessary to parse out the differences.
Furthermore, the potential influence of other downstream processes should be considered. After cellular uptake, the vectors escape the vesicular compartment by externalizing a phospholipase domain and translocate into the host nucleus through the use of nuclear localization signals (Girod et al., 2002; Sonntag, Bleker, Leuchs, Fischer, & Kleinschmidt, 2006) . Once inside the nucleus, virus uncoating leads to the release of packaged genomes to be processed for gene expression (Sipo et al., 2007) . Prior work has also demonstrated that proteasomes may contribute to posttranslational processing of AAV vectors (Denby, Nicklin, & Baker, 2005; Yan et al., 2002) . Further studies addressing the differences at each of these intracellular transduction steps for standard and reverse transduction formats could help explain the results obtained here.
| CONCLUSION
In this study, we directly compared the transduction outcomes of reverse and standard formats with three AAV serotypes (AAV2, providing pAAV2/7 and pAAV2/9. We thank Jeron Chen for his assistance with postacquisition processing of microscopy images.
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